ライフサイエンスコーパス: dosimetry

1 )Lu-lilotomab satetraxetan were included for dosimetry.

2 e assessment of safety, biodistribution, and dosimetry.

3 potential interest for medical and personal dosimetry.

4 ssess pharmacokinetics, biodistribution, and dosimetry.

5 n vitro-to-in vivo extrapolation and reverse dosimetry.

6 8 administration to estimate human radiation dosimetry.

7 lementation is therefore highly dependent on dosimetry.

8 PEB, we performed studies of human radiation dosimetry.

9 ssess pharmacokinetics, biodistribution, and dosimetry.

10 gs relates directly to effective therapeutic dosimetry.

11 ve with improved image quality and radiation dosimetry.

12 remsstrahlung SPECT to improve posttreatment dosimetry.

13 ir comparative biodistribution and radiation dosimetry.

14 valuating (123)I-MNI-420 biodistribution and dosimetry.

15 l (normal organs, lesions) and 3-dimensional dosimetry.

16 l overview of quantitative SPECT imaging for dosimetry.

17 antification-based guidance for radionuclide dosimetry.

18 iNOS levels, and calculated human radiation dosimetry.

19 ondisplaceable binding potential (BPND); and dosimetry.

20 cytometry and in vivo by PET/CT imaging and dosimetry.

21 ll non-Hodgkin lymphoma were included for RM dosimetry.

22 were used to determine pharmacokinetics and dosimetry.

23 y of quantitative imaging for internal renal dosimetry.

24 of long-term toxicity studies and microscale dosimetry.

25 est-retest, 4 men and 1 woman; (18)F-MNI-659 dosimetry, 2 men and 2 women).

26 2) 10 days of personal ultraviolet radiation dosimetry; 3) a sun exposure and physical activity diary

27 alyzed using the 3-dimensional radiobiologic dosimetry (3D-RD) software package.

28 fety, pharmacokinetics, biodistribution, and dosimetry (89)Zr-trastuzumab.

29 90)Y radioembolization planned by predictive dosimetry achieved index tumor regression in 8 of 8 pati

30 ilable data demonstrate that posttherapeutic dosimetry after a first treatment cycle predicts the abs

31 ed to evaluate biodistribution and radiation dosimetry after intravenous injection of (18)F-MCL-524.

32 es, allowing for adequate tumor (90)Y PET/CT dosimetry after radioembolization.

33 ribution and alpha-imaging-based small-scale dosimetry, along with immunohistochemical staining.

34 nzyme, Cambridge, Massachusetts, USA) primed dosimetry also provides an easy way to stimulate the upt

35 1) and (177)Lu-DOTATATE, 3-dimensional voxel dosimetry analysis based on SPECT/CT was performed.

36 Dosimetry analysis revealed that the dose delivered by (

37 intake, together with 10 days of personal UV dosimetry and an associated sun-exposure and physical-ac

38 studies: in the first study, human radiation dosimetry and biodistribution of (11)C-metformin were es

39 review is to summarize available data on the dosimetry and dose-response relationships of several the

40 valent uniform dose cannot handle microscale dosimetry and fails to solve the discordance between the

41 ver 48 h for calculation of tissue radiation dosimetry and for evaluation of clinical safety and effi

42 ose Assessment Resource) method for internal dosimetry and in general concordance with the methodolog

43 acroaggregated albumin SPECT/CT personalized dosimetry and intensification concept with (90)Y-loaded

44 aded glass microspheres using a personalized dosimetry and intensification concept.

45 Of 1,389 participants with dosimetry and known fertility history, 274 were classifi

46 Twenty-one tumors were included for voxel dosimetry and parameters describing dose-volume coverage

47 This article describes the basics of CT dosimetry and PET/CT acquisition in children.

48 hat such NIRS methods can be used to improve dosimetry and to minimize variations of clinical outcome

49 minimization of long-term toxicity, through dosimetry, and adapted to each individual, including rel

50 n these promising findings, biodistribution, dosimetry, and brain kinetic modeling of (11)C-JNJ-42491

51 meters before and after treatment, radiation dosimetry, and complications were recorded.

52 is study evaluated the distribution, safety, dosimetry, and efficacy of (111)In-ABY-025 for determini

53 med to assess the feasibility, tolerability, dosimetry, and efficacy of yttrium-90-labelled anti-CD22

54 in applications such as particle detection, dosimetry, and medical imaging and therapy.

55 rement of effective radical doses by radical dosimetry, and proper normalization of the inherent reac

56 e tumors (NETs) to evaluate biodistribution, dosimetry, and safety.

57 Safety, biodistribution, radiation dosimetry, and the most appropriate imaging time point f

58 Male Sprague-Dawley rats were used to assess dosimetry, antagonistic efficacy via blood pressure meas

59 work, the 3-dimensional Voxel-Based Internal Dosimetry Application (VIDA) and 4D Extended Cardiac Tor

60 The 3-dimensional VIDA dosimetry application Monte Carlo simulation was run usi

61 each subject using the intrathecal-specific dosimetry application.

62 e simplified 3-time-point (1, 48, and 144 h) dosimetry approach deviated by at most 4% in both organ-

63 ne using some simplifying assumptions in the dosimetry approach.

64 Several simplified 3-time-point dosimetry approaches were also evaluated.

65 Quantitative imaging and dosimetry are crucial for individualized treatment durin

66 Radiation dosimetry assessment was performed using pharmacokinetic

67 PET/CT scans for dosimetry assessment were obtained at 10, 60, and 90 min

68 ma xenografts in nude mice was studied for a dosimetry assessment.

69 ingent sensitivity requirements for internal dosimetry assessment.

70 substantial toxicity was consistent with the dosimetry assessments (mean equivalent dose to marrow, 0

71 determine the biodistribution and whole-body dosimetry assessments by positron emission tomography (P

72 SPECT methods and requirements for internal dosimetry at both regional and voxel levels.

73 based on whole-body/-blood clearance (WB/BC) dosimetry at Memorial Sloan Kettering Cancer Center (MSK

74 based on whole-body/-blood clearance (WB/BC) dosimetry at Memorial Sloan Kettering Cancer Center (MSK

75 ry of (99m)Tc-MAA SPECT/CT and posttreatment dosimetry based on (90)Y time-of-flight (TOF) PET/CT.

76 Dosimetry based on (99m)Tc-MAA SPECT/CT can be used for

77 n (90)Y radioembolization of HCC, predictive dosimetry based on (99m)Tc-MAA SPECT/CT provided good es

78 Microscale kidney dosimetry based on alpha-camera images and a nephron mod

79 8 min, Ebeta(+)av = 830 keV) for imaging and dosimetry before (177)Lu-based radionuclide therapy.

80 valid alternative to (68)Ga for imaging and dosimetry before (177)Lu-radionuclide tumor therapy.

81 is first-in-human study demonstrated safety, dosimetry, biodistribution, and successful HER2-targeted

82 ings by a first-in-human (11)C-metformin PET dosimetry, biodistribution, and tissue kinetics study.

83 rience with (18)F-FEOBV, including radiation dosimetry, biodistribution, tolerability and safety in h

84 Image-guided personalized predictive dosimetry by artery-specific SPECT/CT partition modeling

85 luded and the male model was applied for the dosimetry calculation, and the mean effective dose was e

86 tively poor spatial resolution and imprecise dosimetry calculation.

87 Dosimetry calculations and observed radiation-induced ef

88 Dosimetry calculations indicate promise for future (90)Y

89 Dosimetry calculations predict that 370 MBq of (51)Mn in

90 Moreover, dosimetry calculations revealed that radionuclide-labele

91 Further, dosimetry calculations revealed that the (64)Cu pretarge

92 Dosimetry calculations revealed that the pretargeting sy

93 Dosimetry calculations showed a tumor-absorbed dose of 4

94 Dosimetry calculations were performed using OLINDA/EXM 1

95 Dosimetry calculations were then performed using OLINDA/

96 ed and used to determine residence times for dosimetry calculations.

97 agent-related toxicity, consistent with the dosimetry calculations.

98 tribution data were used for mouse and human dosimetry calculations.

99 e group, pretherapeutic (124)I PET/CT lesion dosimetry can be used as a prognostic tool to predict le

100 Human normal-organ kinetics, radiation dosimetry, clinical safety, and imaging efficacy provide

101 y, hepatopulmonary shunting, and appropriate dosimetry considerations.

102 ass microspheres and determine whether tumor dosimetry could predict response and survival.

103 dination of benzamides and report on initial dosimetry data and the first therapeutic application of

104 Dosimetry data for the 2 radiotracers were compared.

105 However, no human dosimetry data have been published.

106 ned for the use of computed tomographic (CT) dosimetry data in this study.

107 moral uptake, biodistribution, and radiation dosimetry data provide strong preclinical evidence that

108 Our dosimetry data showed that a 370-MBq injection of (18)F-

109 brolizumab in vivo, while providing detailed dosimetry data that may lead to better dosing strategies

110 A-617 therapies were cautiously derived from dosimetry data, but their practical appropriateness has

111 (68)Ga-pentixafor exhibits a favorable dosimetry, delivering absorbed doses to organs that are

112 (68)Ga-PSMA I&T exhibits a favorable dosimetry, delivering organ doses that are comparable to

113 Current standard values of fetal dosimetry deriving from (18)F-FDG injection in pregnant

114 A dosimetry estimate was calculated on the basis of time-a

115 red over 6 h for (18)F-MNI-659 and radiation dosimetry estimated with OLINDA.

116 The aim of this study was to provide dosimetry estimates for (18)F-FSPG based on human whole-

117 Dosimetry estimates for 1 MBq of (225)Ac-PSMA-617 assumi

118 r the study derives from the need to perform dosimetry estimates for the corresponding (90)Y-labeled

119 Dosimetry estimates from OLINDA demonstrated that the or

120 Dosimetry estimates from OLINDA showed that the organs r

121 Radiation dosimetry estimates indicate that more than 400 MBq may

122 Dosimetry estimates indicate that the kidney is the dose

123 kinetic properties, test-retest results, and dosimetry estimates of (123)I-MNI-420, a SPECT radiotrac

124 number of disintegrations, and production of dosimetry estimates were performed using the RADAR (RAdi

125 -body PET images were acquired for radiation dosimetry estimates.

126 pecific VIDA implementation enables tailored dosimetry estimation for regions most relevant in intrat

127 slation of (64)Cu-FBP8, we performed a human dosimetry estimation using time-dependent biodistributio

128 al formulations, and the predicted radiation dosimetry estimations for some organs varied significant

129 %IDs) corrected for radioactive decay in all dosimetry-evaluable subjects at 15 min and 4 h were 1.9%

130 Similarly in the lungs, the %ID for all dosimetry-evaluable subjects was 4.9% at 15 min after in

131 Based on the biokinetics, a dosimetry evaluation for humans suggests that (188)Re-ZH

132 mplex dynamics, whereas photobleaching-based dosimetry failed under hypoxic conditions.

133 Organ-specific and whole-body dosimetries for (68)Ga-DOTATATE were similar to but ofte

134 The radiation dosimetry for (11)C-CNS5161 for a standard single inject

135 and tumors determined by (124)I PET/CT-based dosimetry for (131)I therapy of metastatic DTC when the

136 The radiation dosimetry for (18)F-FETrp determined from the mouse data

137 herein assess the cytotoxicity and radiation dosimetry for (68)Ga-NOTA-UBI and a first-in-human evalu

138 s study was to derive PET/CT-based radiation dosimetry for (89)Zr-cetuximab, with special emphasis on

139 (64)Cu-LLP2A displayed favorable dosimetry for human studies and is a potential imaging c

140 d to the development of new, simple chemical dosimetry for low dose detection of gamma radiation.

141 y biodistribution and estimate the radiation dosimetry from (11)C-CURB scans in humans.

142 Dosimetry from multi-time-point PET imaging was performe

143 were studied-a kinetic analysis group and a dosimetry group.

144 dict the average ADs after administration of dosimetry-guided (131)I activity.

145 ies for differentiated thyroid cancer, blood dosimetry has been developed to estimate the maximum tol

146 For tumor dosimetry, imaging at a later time than the routinely us

147 ted for distribution, binding, and radiation dosimetry in a healthy cynomolgus monkey.

148 describe the clinical application of (124)I dosimetry in a patient who had radioiodine-refractory th

149 particle transport, and thus attain accurate dosimetry in cell culture systems, which will greatly ad

150 ing provides a better assessment of lesional dosimetry in contrast to traditional I-131 whole body sc

151 ssess safety, biodistribution, and radiation dosimetry in humans for the highly selective sigma-1 rec

152 PRRT have been concentrated to normal organ dosimetry in order to limit side effects.

153 planned tumor dose [T(plan) D]) and nontumor dosimetry in patients treated by (90)Y-loaded glass micr

154 Dosimetry in peptide receptor radionuclide therapy using

155 ticular, we discuss the role of (124)I-based dosimetry in targeting of the sodium-iodine symporter an

156 t optimization of a personalized Monte Carlo dosimetry in the context of SIRT was confirmed in this s

157 was to evaluate SPECT- and MR imaging-based dosimetry in the first patients treated with (166)Ho rad

158 ow of the importance of in vitro and in vivo dosimetry in the hazard assessment and ranking of engine

159 7 of 8 patients, including 2 by sublesional dosimetry, in 1 of whom there was radioembolization lobe

160 ety, biodistribution, and internal radiation dosimetry, in humans with thyroid cancer, of (18)F-tetra

161 col based on such a methodology for in vitro dosimetry, including detailed standardized procedures fo

162 rom MgO:Li,Ce,Sm has suitable properties for dosimetry, including high sensitivity to ionizing radiat

163 Laboratory reporting of radiation dosimetry is a critical component of creating a quality

164 Finally, (18)F-MNI-659 dosimetry is favorable and consistent with values report

165 ith the use of (166)Ho-microspheres, in vivo dosimetry is feasible on the basis of both SPECT and MR

166 la: see text] demonstrates that pretreatment dosimetry is particularly suitable for minimizing radiat

167 An important key to accurate in vitro dosimetry is the characterization of sedimentation and d

168 Bq/kg dose was not feasible because of organ dosimetry limits; however, 3 assigned patients were eval

169 ssed the feasibility of generating radiation dosimetry maps in liver regions with high and low (90)Y

170 We suggest routine dosimetry measurement of eye lens and proper protection

171 nt with the range obtained with conventional dosimetry methods.

172 This paper presents a small-scale dosimetry model for calculation of S factors for several

173 was estimated using a Multiple-Path Particle Dosimetry model.

174 ation exposure was calculated via an updated dosimetry model.

175 biodistribution, pharmacokinetics, estimated dosimetry, nano-SPECT/CT, and bioluminescent imaging sug

176 will significantly alter in vitro behavior (dosimetry, NP uptake, cytotoxicity), as well as in vivo

177 ET/CT was used to characterize the radiation dosimetry of (11)C-DPA-713, a specific PET ligand for th

178 e use of (11)C-laniquidar by determining the dosimetry of (11)C-laniquidar using whole-body PET studi

179 we determined the human whole-body and organ dosimetry of (18)F-clofarabine.

180 he initial clinical experience and radiation dosimetry of (18)F-DCFBC in men with metastatic PCa.

181 tudy was to evaluate the biodistribution and dosimetry of (18)F-FAZA in non-small cell lung cancer pa

182 erwent imaging to verify the human radiation dosimetry of (18)F-FTT.

183 e safety, feasibility, pharmacokinetics, and dosimetry of (18)F-MFBG in neuroendocrine tumors (NETs).

184 Our objective was to model the cellular dosimetry of (64)Cu under different geometries commonly

185 the biodistribution, kinetics, and radiation dosimetry of (64)CuCl2 in humans and to assess the abili

186 tion, kinetics of the lesions, and radiation dosimetry of (64)CuCl2 were evaluated.

187 e biodistribution and estimate the radiation dosimetry of (68)Ga-ABY-025 for 2 different peptide mass

188 macokinetics, biodistribution, and radiation dosimetry of (68)Ga-bombesin antagonist (68)Ga-DOTA-4-am

189 Reporting of measured dosimetry of (68)Ga-DOTATATE could be useful for investi

190 The measured human dosimetry of (68)Ga-DOTATATE is similar to that of other

191 The whole-body distribution and radiation dosimetry of (68)Ga-pentixafor were evaluated.

192 -in-human study, we evaluated the safety and dosimetry of (89)Zr-pertuzumab PET/CT for human epiderma

193 to evaluate agreement between the predictive dosimetry of (99m)Tc-MAA SPECT/CT and posttreatment dosi

194 usly reported pharmacokinetic properties and dosimetry of 8, make it a potential agent for both PET i

195 mans was designed to evaluate the safety and dosimetry of a cellular proliferative marker, N-(4-(6,7-

196 ed the whole-body distribution and radiation dosimetry of both radiotracers in humans.

197 , whole-organ biodistribution, and radiation dosimetry of LMI1195 were evaluated in a phase 1 clinica

198 Dosimetry of organs and tumors helps to assess risks and

199 d the pharmacokinetics, biodistribution, and dosimetry of pembrolizumab in vivo, accomplished through

200 Measured human dosimetry of the (68)Ga-labeled synthetic somatostatin a

201 her one can really use the former to predict dosimetry of the latter.

202 were extrapolated to humans to estimate the dosimetry of the tracer.

203 Whole-body distribution and radiation dosimetry of this new probe were evaluated.

204 131)I therapy for the normal organs with the dosimetry package 3D-RD.

205 From the radiation dosimetry perspective, the apoptosis imaging agent (18)F

206 Radiation dosimetry PET/CT experiments indicated that most human o

207 antitative SPECT/CT imaging, a set of kidney dosimetry phantoms and their spherical counterparts was

208 The estimates of radiation dosimetry, pharmacokinetic parameters, and safety profil

209 e study was conducted to calculate the tumor dosimetry (planned tumor dose [T(plan) D]) and nontumor

210 osimetry technique--personalized Monte Carlo dosimetry (PMCD)-based on patient-specific data and Mont

211 on (TARE) using pretreatment partition model dosimetry (PMD).

212 Therefore, from a radiation dosimetry point of view, HD is preferred for PET/CT eval

213 Therefore, from a radiation dosimetry point of view, there is no preference for eith

214 nCl2 in mice, and performs preliminary human dosimetry predictions.

215 While a surface area dosimetry presented an improvement over mass when DOC wa

216 Pretreatment dosimetry prior to I-131 treatment for patients with adv

217 18)F-D4-FCH is a safe PET radiotracer with a dosimetry profile comparable to other common (18)F PET t

218 (18)F-ICMT-11 is a safe PET tracer with a dosimetry profile comparable to other common (18)F PET t

219 lects PARP expression and that its radiation dosimetry profile is compatible with those of agents cur

220 ety, biodistribution, and internal radiation dosimetry profiles of (18)F-D4-FCH in 8 healthy human vo

221 ety, biodistribution, and internal radiation dosimetry profiles of (18)F-ICMT-11 in 8 healthy human v

222 bes was conducted that included internal BPA dosimetry, progression to adenocarcinoma with aging and

223 The pretherapy blood dosimetry protocol can be substantially shortened and ma

224 this study was to develop an individualized dosimetry protocol for the bone marrow.

225 gamma-camera imaging as part of the clinical dosimetry protocol, determination of the whole-body acti

226 ry techniques conventionally used in hepatic dosimetry provide a first-order estimate of absorbed dos

227 tine use of WB/BC dosimetry without lesional dosimetry provided no OS advantage when compared with em

228 tine use of WB/BC dosimetry without lesional dosimetry provided no OS advantage when compared with em

229 e addressed in clinical trials incorporating dosimetry-related concepts for determining the amount of

230 Partition-model predictive dosimetry relies on differential tumor-to-nontumor perfu

231 The need for accurate in vitro dosimetry remains a major obstacle to the development of

232 Pretreatment dosimetry remains important to optimize the I-131 treatm

233 ne, although the impact of reducing lesional dosimetry requires attention and further investigation.

234 After encouraging preclinical and human dosimetry results for the novel estrogen receptor (ER) P

235 Safety dosimetry revealed kidney doses of approximately 0.75 Gy

236 sionate use, describing the biodistribution, dosimetry, safety, and clinical activity of radretumab.

237 To evaluate radiotracer biodistribution and dosimetry, serial whole-body images were acquired immedi

238 and AOP approaches and suggest that internal dosimetry should be monitored to advance an understandin

239 Dosimetry shows that conventional muCT usually does not

240 The measured dosimetry shows that the critical organ with (68)Ga-DOTA

241 of a proven 3-dimensional (3D) personalized dosimetry software, 3D-RD, and applied to the myeloablat

242 cted to improve the relevance of small-scale dosimetry studies and thus to accelerate the optimizatio

243 PET imaging, biodistribution, and dosimetry studies in mice, as well as immunohistochemica

244 istribution, pharmacokinetics, SPECT/CT, and dosimetry studies were performed to assess the bioequiva

245 Tumor uptake, biodistribution, and dosimetry studies were performed to evaluate the efficac

246 s therefore not a surrogate for (90)Y-OPS201 dosimetry studies.

247 The dosimetry study provided an effective dose of less than

248 For the dosimetry study, the highest organ dose was in the liver

249 Eight patients were included for the tumor dosimetry study.

250 Mouse dosimetry suggested that this should allow for an 8-fold

251 CTDIvol was estimated using the ImPACT CTDI dosimetry tables.

252 n that context, a 3-dimensional personalized dosimetry technique--personalized Monte Carlo dosimetry

253 icrosphere distribution confirmed that (90)Y dosimetry techniques conventionally used in hepatic dosi

254 To perform voxel dosimetry, the SPECT/CT data and an in-house-developed M

255 mics-based approaches to forward and reverse dosimetry, there is currently a lack of user-friendly, f

256 Eight of these 12 patients reached the dosimetry threshold for radioiodine therapy, including a

257 quantitation of SPECT imaging and its use in dosimetry to guide therapies, it is desirable to underst

258 estimates for common organs in a preexisting dosimetry tool (OLINDA/EXM).

259 Radiobiologic and quantitative imaging-based dosimetry tools are now available that enable rational i

260 round state relaxation within the principal (dosimetry) trap.

261 within +/-9% of that measured by using film dosimetry under the condition of matched-phantom geometr

262 otracers, preclinical (i.e., animal-derived) dosimetry underestimates the ED to humans, in the curren

263 s should be done to enhance the precision of dosimetry, validate the maximum tolerable dose, and eval

264 ent communication offers a revision of fetal dosimetry values calculated from recently published huma

265 Average dosimetry values were used for analysis.

266 Radiation dosimetry was acceptable, with effective doses of 9.5 mu

267 Microscale dosimetry was assessed in the realistic liver model deve

268 s analyzed for 11 organs using MIM software; dosimetry was assessed using OLINDA/EXM.

269 Dosimetry was based on SPECT (n = 15) and MR imaging (n

270 Dosimetry was calculated using the OLINDA/EXM software.

271 Dosimetry was calculated using the OLINDA/EXM software.

272 In advance of human studies, radiation dosimetry was determined in nonhuman primates.

273 Radiotracer distribution and dosimetry was determined using serial whole-body PET ima

274 Radiation dosimetry was estimated by whole-body PET of a single hu

275 Radiation dosimetry was favorable (effective dose, 5.2 muSv/MBq).

276 es using pretherapeutic (124)I PET/CT lesion dosimetry was found.

277 n of shielding conditions for which reliable dosimetry was impossible.

278 ed using alpha-camera images, and microscale dosimetry was modeled.

279 Pretherapeutic (177)Lu-pentixather dosimetry was performed before (177)Lu-pentixather or (9

280 n as a function of time were determined, and dosimetry was performed for a range of organs including

281 Dosimetry was performed in 30 patients.

282 Dosimetry was performed in three of the cadavers by acce

283 Radiation dosimetry was performed to estimate radiation dose to th

284 -24 MeV) and its impact on image quality and dosimetry was required.

285 Dosimetry was then measured for the whole body and for s

286 Aiming at a simplification of dosimetry, we analyzed the accuracy of a theoretically s

287 Using these data to predict patient dosimetry, we found a kidney, pancreas, and liver exposu

288 id cancer patients who received (124)I blood dosimetries were retrospectively analyzed.

289 The biodistribution and radiation dosimetry were assessed by serial whole-body PET/CT scan

290 (211)At localization and small-scale dosimetry were assessed using two alpha-imaging systems:

291 curves were calculated, and organ uptake and dosimetry were estimated.

292 ring therapy, pharmacokinetics and radiation dosimetry were evaluated.

293 The biodistribution of (18)F-ISO-1 and human dosimetry were evaluated.

294 istribution, pharmacokinetics, and radiation dosimetry were performed on nonhuman primates.

295 t of tissue density heterogeneities (TDH) on dosimetry when using a DK method and to propose a simple

296 We performed measured dosimetry with (68)Ga-DOTATATE PET/CT scanning in 6 volu

297 (11)C-sarcosine showed a favorable radiation dosimetry with an effective dose estimate of 0.0045 mSv/

298 After stimulation with thyrotropin alfa, dosimetry with iodine-124 positron-emission tomography (

299 Conclusion: Routine use of WB/BC dosimetry without lesional dosimetry provided no OS adva

300 Routine use of WB/BC dosimetry without lesional dosimetry provided no OS adva